Virology Testing Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Virology Testing Market Trends and Insights

Rising Prevalence of Viral Diseases

Outbreaks such as 61 U.S. human H5N1 cases in 2024-2025 pressed state labs to expand PCR capacity. Mpox clade Ib detections in Central Africa triggered WHO emergency declarations that accelerated real-time PCR rollouts.^{[2]Centers for Disease Control and Prevention, “Avian Influenza A(H5N1) Virus,” cdc.gov} Chronic programs, for example Egypt’s hepatitis C elimination effort, maintain repeat viral-load testing. These parallel clinical and public-health needs sustain demand for flexible multiplex systems that accept new targets without hardware replacement. Dense populations and expanding access in Asia-Pacific and sub-Saharan Africa amplify volume growth, underpinning the 1.2 percentage-point lift in the global CAGR.

Growing Regulatory Clearances for Novel Assays

The FDA’s breakthrough-device pathway shortened review cycles, exemplified by QIAGEN’s QIAstat-Dx Rise, cleared in September 2025 after an expedited process.^{[3]QIAGEN, “FDA Clearance for QIAstat-Dx Rise,” qiagen.com} Europe’s IVDR, despite deadline extensions, is consolidating suppliers as smaller firms exit rather than absorb high conformity costs. Harmonized guidelines from the International Medical Device Regulators Forum encourage simultaneous submissions, accelerating global launches and adding 0.9 percentage points to the CAGR in developed markets.

Rapid Adoption of Molecular POC PCR Platforms

Cepheid’s GeneXpert network now exceeds 30,000 placements, giving emergency departments rapid triage capability. Abbott’s ID NOW surpasses 100,000 units and returns influenza A/B or SARS-CoV-2 results in 13 minutes. A 2024 Journal of Clinical Microbiology study found point-of-care molecular testing cut hospital stay by 1.2 days, saving USD 2,400 per admission. QIAGEN’s QIAstat-Dx Rise fills the mid-volume gap at 160 continuous samples daily. CLIA waiver extensions broaden the addressable market to roughly 200,000 U.S. physician-office labs, giving the driver a 1.4 percentage-point push.

Expansion of Wastewater-Based Viral Surveillance

The CDC’s National Wastewater Surveillance System spans 1,500 U.S. plants, tracking SARS-CoV-2, influenza A, RSV and mpox. Australia will roll out a nationwide pathogen network in early 2026. The UK evaluated automated liquid-handling and PCR workcells that allow seven-day operation without weekend staff, demonstrating labor savings. Standardized reagent kits tailored to inhibitor-rich wastewater matrices form a new, season-independent consumable stream that lifts CAGR by 0.7 percentage points.

Stringent Product-Approval Regulations

IVDR compliance costs can top EUR 500,000 per device family, and notified-body capacity is limited to 30 organizations, creating year-long approval queues. India adopted local-validation rules in 2024, adding further complexity. Smaller assay makers are leaving the EU, narrowing menu variety and shaving 0.5 percentage points off CAGR during the transition.

Reimbursement & Pricing Reforms in Key Markets

CMS cut the Clinical Laboratory Fee Schedule 1.3% in 2025 and Medicare Advantage plans imposed prior authorization for costly molecular tests. Germany’s payer networks negotiated 15%-20% discounts on respiratory panels in 2024. These pricing pressures subtract 0.7 percentage points from CAGR in the short term.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Type: Instruments Drive Capital Refresh Cycles

Instruments will climb at a 6.76% pace to 2031, outstripping the overall virology testing market. Hospitals are buying integrated PCR workcells such as Roche’s cobas 5800 to overcome staffing gaps and compress turnaround. Consumables still generated 62.46% of 2025 revenue, anchoring the virology testing market size with recurring sales. Instruments, however, carry 50%-60% gross margins and deliver service-contract annuities, fostering vendor lock-in. Public-sector budget caps in Europe temper adoption, but automation imperatives keep the sub-segment on a faster trajectory.

Consumables will continue to dominate revenue through 2031 as wastewater programs and chronic-disease monitoring lift test volumes. Even so, capital budgets are prioritizing multi-panel PCR systems that accept respiratory, STI and bloodborne targets on a single chassis, keeping instrument growth lively. Validation costs and staff-training hurdles create switching friction that benefits established vendors.

By Diagnostic Technique: Molecular Methods Sustain Dominance

Molecular methods captured 49.26% of 2025 dollars and will advance at a 6.67% clip, steering the virology testing market share toward higher-complexity assays. PCR remains the backbone, bolstered by CLIA-waived cartridges like Xpert Bordetella pertussis. 

Falling sequencing costs—USD 200-300 per sample on Illumina’s NextSeq 1000/2000—are making NGS surveillance feasible for routine outbreak response. Immunoassays lose ground as molecular platforms match turnaround speed at declining prices. Mass-spectrometry stays niche for viral work, and culture techniques remain isolated to reference labs.

By Testing Setting: At-Home Testing Rebounds Post-Pandemic

At-home testing will rebound at a 6.81% CAGR, led by FDA-cleared OTC combo tests for flu and SARS-CoV-2. Centralized labs still held 47.89% of 2025 revenue owing to viral-load and genotyping services. 

Point-of-care systems like GeneXpert and ID NOW bridge the gap, enabling sub-hour results within clinical workflows. Quality-control warnings from FDA in 2024 spotlight the need for rigorous validation as home tests extend into STI and hepatitis categories.

By End User: Hospitals Gain Share Through Vertical Integration

Hospitals and clinics will edge up at 6.78% through 2031 as health systems internalize testing to curb send-out fees and capture technical revenue. Mid-throughput solutions such as QIAstat-Dx Rise fit hospital daily volumes without batch delays. 

Public-health agencies, meanwhile, represent strategic demand anchored in wastewater surveillance, while reference labs grapple with margin compression under CLFS cuts.

Geography Analysis

Asia-Pacific’s rapid infrastructure spend and infectious-disease burden position the region for the fastest ascent, even as North America continues to supply 40.23% of 2025 sales. China’s domestic firms leverage lower pricing to win tenders, while India deploys 1,000 district-level PCR labs by 2027. Australia’s nationwide wastewater network exemplifies policy-driven demand outside clinical cycles.  

Europe, holding roughly one-quarter of 2025 revenue, is constrained by IVDR compliance costs that push smaller vendors out, narrowing instrument menus but solidifying demand for big-platform replacements. Bulk-purchase price deals in Germany and France hold down ASPs.  

Middle East and Africa expand regional hubs to meet fast-response regulations, yet donor-funding cuts threaten sub-Saharan HIV testing continuity. South America adds capacity via public-private deals, but foreign-exchange swings hamper reagent imports, moderating growth.

Regulatory Landscape

Virology testing products operate under tightening in vitro diagnostic (IVD) controls that increasingly distinguish emergency, point-of-care, and laboratory-developed pathways. In the United States, FDA actions in 2025 and 2026 reinforced this direction, including a September 2025 final guidance describing enforcement policies for IVD tests during Section 564 declared emergencies and a June 2026 Federal Register final order that classifies certain SARS-CoV-2 point-of-care devices into class II with special controls, which strengthens post-emergency commercialization requirements.

In Europe, the IVDR transition continues to shape assay availability and supplier participation, with notified-body capacity constraints influencing certification timelines for higher-risk IVDs. Globally, WHO updated its IVD prequalification approach in 2026 by separating performance evaluation from the broader assessment process and revising fee structures, which shifts compliance workload for suppliers targeting tender-driven and donor-funded programs in low- and middle-income countries.

Value Chain Analysis

The virology testing value chain runs from raw-material suppliers (antibodies, enzymes, plastics, oligos) to assay and instrument OEMs, contract development and manufacturing partners, logistics providers (including cold chain), and multi-tier distribution into hospitals, reference labs, and public-health agencies. Large OEMs such as Roche, Abbott, Thermo Fisher, and Danaher (Cepheid) anchor demand through installed bases and closed consumables, while specialist upstream providers such as Fujirebio supply critical IVD components and offer OEM/CDMO services that support menu expansion and private-label production.

Bottlenecks remain around high-purity enzymes and polymerases, specialized plastics and injection-molding capacity for high-throughput consumables, and temperature-sensitive reagent distribution, which can affect lead times during seasonal surges or outbreak response. Evidence of resilience-building includes protocol-level flexibility efforts (for example, validated alternative reagents published for molecular workflows in 2025) and improving availability perceptions in the laboratory channel, where a 2025 industry survey reported higher supply adequacy than in 2024, reflecting normalization after pandemic-era constraints.

Market Opportunities and Future Outlook

Decentralized and surge-ready molecular capacity is a key whitespace area, backed by wastewater surveillance expansion and regional laboratory infrastructure programs. The CDCs National Wastewater Surveillance System operates across about 1,500 US plants, and Australias planned nationwide pathogen network rollout in early 2026 is translating surveillance into repeat, matrix-specific consumable demand and standardized workflows that are less dependent on seasonal clinical volumes.

Product and technology whitespace is also forming around high-throughput sample-to-answer systems, ultra-precision digital PCR standardization, and field-validated CRISPR assays that reduce sample prep and instrument burden. In June 2026, Bruker launched the MyGenius PRO high-throughput PCR-based sample-to-answer molecular diagnostics system, and in South Korea, BioTNS was selected in June 2026 to host a government program (KRW 30 billion) focused on establishing technical standards for ultra-precision dPCR diagnostics, signaling institutional backing for performance and comparability in next-generation quantitative virology testing. Regional capability build-out further supports demand formation, including the July 2026 designation of the Uganda Virus Research Institute as an East African Community regional centre of excellence in virology, which expands the addressable base for instruments, assays, and training-linked services in emerging markets.